Trendlines says its most valuable portfolio company is Stimatix
Stimatix sold its assets in Nov 2014 to a B Braun subsidiary; Trendlines' current holding of 28.2% valued at US$42.6m
Singapore
CATALIST-LISTED The Trendlines Group - an Israel and Singapore-based incubator of medtech and agritech startups - has disclosed that an asset it described as its "Most Valuable Portfolio Company" is Stimatix GI.
In a statement on Monday, Trendlines said that Stimatix, which develops medical products to aid patients with intestinal blockage, sold its assets in November 2014 to a subsidiary of German medical device company B Braun Group. B Braun will market Stimatix's ostomy products internationally from mid-2018.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Gold prices tick higher on US rate cut bets
Nomura targets 20% revenue growth from global markets business
FLCT posts 1.1% lower H1 DPU of S$0.0348 on higher vacancies, expenses
Singapore shares rise at Tuesday’s open tracking global rally; STI up 0.2%
Segantii allegations roil a go-to block trader for global banks
ETF popularity poised to stay as investors flock to diversification, stability